Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation

被引:7
|
作者
Vij, R
Brown, R
Shenoy, S
Haug, JS
Kaesberg, D
Adkins, D
Goodnough, LT
Khoury, H
DiPersio, J
机构
[1] Washington Univ, Sch Med, Div Bone Marrow Transplantat & Stem Cell Biol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pediat Hematol, St Louis, MO 63110 USA
关键词
CD34; selection; allogeneic transplantation; GVHD; dendritic cells; cytokines;
D O I
10.1038/sj.bmt.1702427
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
GVHD is a significant cause of morbidity and mortality following allogeneic peripheral blood stem cell transplantation (AlloPBSC). CD34(+) cell selection could reduce GVHD by negative selection of T cells. In an attempt to reduce the T cell content of alloPBSC we carried out a trial in which 11 patients with hematologic malignancies received alloPBSC from HLA-matched siblings following density gradient separation using an isotonic colloidal silica solution (BDS 60; Dendreon Corporation). Cyclosporine and methylprednisone were used for GVHD prophylaxis. The mean yield of CD34(+) cells was 69 +/- 15.6% with a purity of 2.9 +/- 1.7%. The mean number of CD3(+) cells infused was 1.0 +/- 1.2 x 10(7)/kg, representing a 1.3 log depletion. A high risk of acute GVHD was observed: grade II-IV in 7/11 (64%) and grade III-IV GVHD in 5/11 (45%) patients. Nine of the 11 (82%) patients died with a median survival of 68 days. Cytokine expression in PBSC was compared pre and post processing. Interferon-gamma was detected only following density gradient separation while IL-8 expression increased 3- to 6-fold post processing. Therefore, processing with this device may augment production of pro-inflammatory cytokines.
引用
收藏
页码:1223 / 1228
页数:6
相关论文
共 50 条
  • [21] Autologous and allogeneic transplantation with peripheral blood CD34+ cells:: a pediatric experience
    Watanabe, T
    Kawano, Y
    Watanabe, A
    Takaue, Y
    HAEMATOLOGICA, 1999, 84 (02) : 167 - 176
  • [22] CD34+ selection using density gradient separation does not reduce the risk of graft vs host disease after allogeneic peripheral blood stem cell (PBSC) transplant.
    Vij, R
    Brown, R
    Haug, JS
    Todd, G
    Adkins, D
    Goodnough, LT
    Khoury, H
    Westervelt, P
    DiPersio, J
    BLOOD, 1998, 92 (10) : 649A - 649A
  • [23] Impact of CD34+ Stem Cell Dose on Engraftment Period in Allogeneic Peripheral Blood Stem Cell Transplanted Patients
    Suria, A. A.
    Diyana, Hazlina B.
    Zakari, Zed A. H.
    Nurasyikin, Y.
    Yousuf, R.
    Azma, R. Z.
    MEDICINE AND HEALTH, 2021, 16 (01): : 39 - 49
  • [24] CD34+selected autologous peripheral blood stem cell transplantation (CD34+/ASCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Marín, P
    Martínez, C
    Rovira, M
    Villamor, N
    Aymerich, M
    Lozano, M
    Fernández-Avilés, F
    Urbano-Ispizua, A
    Berenguer, J
    Arbizu, T
    Montserrat, E
    Graus, F
    BONE MARROW TRANSPLANTATION, 2003, 31 : S16 - S16
  • [25] Autologous CD34+selected peripheral blood stem cell transplantation (CD34+/PBSCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Graus, F
    Marín, P
    Martínez, C
    Rovira, M
    Urbano-Ispizua, A
    Arbizu, T
    Casanova, B
    Mercader, JM
    Mazzara, R
    Merino, A
    Tolosa, E
    Montserrat, E
    BLOOD, 1999, 94 (10) : 398B - 398B
  • [26] High frequency of complete donor chimerism following allogeneic transplantation of CD34+ selected peripheral blood progenitor cells (allo PBPCT/CD34+)
    Briones, J
    UrbanoIspizua, A
    Lawler, M
    Rozman, C
    Gardiner, N
    Martinez, C
    McCann, S
    Montserrat, E
    BLOOD, 1996, 88 (10) : 442 - 442
  • [27] Comparison of immune recovery following allogeneic peripheral blood progenitor cell transplantation with and without CD34+ positive selection.
    Gutiérrez, AM
    Solano, C
    Benet, I
    Sarsotti, E
    Arbona, C
    Prósper, F
    Tormo, M
    Terol, MJ
    Marugán, I
    Conde, JG
    BLOOD, 1999, 94 (10) : 319A - 319A
  • [28] Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies
    Das, Tongted
    North, Daniel
    Fleming, Shaun
    Kliman, David
    Spencer, Andrew
    Wei, Andrew H.
    Patil, Sushrut S.
    Widjaja, Jacueline
    O'Brien, Maureen
    Curtis, David J.
    BLOOD, 2020, 136
  • [29] Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in older patients with advanced hematologic malignancy
    Schiller, G
    Rowley, S
    Buckner, CD
    Berenson, R
    Benyunes, M
    Appelbaum, FR
    Bensinger, WI
    BLOOD, 1995, 86 (10) : 1545 - 1545
  • [30] Autologous CD34+ selected peripheral stem cell transplantation (ASCT/CD34+) for multiple sclerosis (MS).
    Carreras, E
    Saiz, A
    Graus, F
    Marín, P
    Urbano-Ispizua, A
    Mercader, JM
    Martínez, C
    Rovira, M
    Mazzara, R
    Merino, A
    Tolosa, E
    Montserrat, E
    BONE MARROW TRANSPLANTATION, 1999, 23 : S33 - S33